Navigation Links
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Date:6/24/2008

of 2008, with initial data expected shortly thereafter.

About AGENDA

AGENDA is a global Phase 3, randomized, double-blind trial in patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from an antecedent randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood. Analysis of those efficacy outcomes in GM301, which were observed in 274 patients, showed the following results:

Hazard

Endpoint Genasense/DTIC DTIC Ratio P

Overall response 20.8% 7.2% 0.002

Durable response 10.7% 2.4% 0.007

Progression-free 3.6 mos. 1.6 mos. 0.58 < 0.0001

survival, median

Overall survival, 12.3 mos. 9.9 mos. 0.64 0.0009

median

A scientific article that describes efficacy and safety results from GM301 can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1

About the EADO

The EADO is an independent non-profit organization dedicated to the promotion, coordination, and improvement of clinical and laboratory research activities in the field of skin cancer. The organization has an European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of dermato-oncology. EADO provides leadership by formulating and disseminating quality standards and
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
2. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Genta Clinical Programs Featured at American Society of Hematology Meeting
11. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... TAMPA, Fla. , Sept. 15, 2014 ... Dr. Steven Stanos with an expanded role ... program. Dr. Stanos, a nationally recognized physiatrist ... on topics related to rehabilitation and workers, compensation, is ... medicine by the American Board of Pain Medicine and ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-FirstCall/ --,Wyeth Pharmaceuticals, ... a,re- analysis of pooled data from both hormone ... published today in the,Journal of the American Medical ... coronary heart disease for women who,initiate hormone therapy ...
... superior sustained pain-free results compared to,sumatriptan, RESEARCH ... 03, 2007,/PRNewswire-FirstCall/ -- -- Findings from two ... sufferers demonstrated that,Trexima(TM) provided superior headache relief ... placebo, and two through 24-hour sustained,pain-free results ...
Cached Medicine Technology:New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 2New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 3New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 4New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 5New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 6Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 2Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 3Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 4Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 5
(Date:9/16/2014)... Louisiana (PRWEB) September 16, 2014 New ... an amazing new product for corporate wellness programs and ... Kit. , “In the past, cholesterol screening was ... large amount of products, variable SKUs and storage space ... “With our Universal Cholesterol Screening Kits, it’s easy: one ...
(Date:9/16/2014)... Pass, OR (PRWEB) September 16, 2014 ... is experiencing a major extended drought crisis that in ... survival. Grigg praises the many individuals who are dedicated ... fresh water policy solutions overlook large portion of the ... new, possibly worse crises.     , Grigg explained his, “total ...
(Date:9/16/2014)... 2014 Oxnard dentist and ... Dental Art Institute in Oxnard and Woodland Hills, Calif., ... weekend. , Dr. Jivraj, an expert in teeth restoration ... in his presentation “Clinical and Laboratory Aspects of ... p.m. Saturday, Sept. 20, at the Empire Landmark Hotel ...
(Date:9/16/2014)... On September 14, the HearStrong Foundation ... Bills Alumni Foundation VIP Tailgate event outside Ralph Wilson ... NFL Hall-of-Famer Joe DeLamielleure, who also experiences hearing ... her dedication in overcoming hearing difficulties to achieve her ... community to do the same. , Nominated by Hearing ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
Breaking Medicine News(10 mins):Health News:New Line Medical Launches Universal Cholesterol Screening Kits 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3
... the monotone of an instructor or insufficient rest the night ... trouble staying awake in class. Researchers have now found a ... awake during class, and it doesn't have anything to do ... alertness by applying acupressure at stimulation points to keep themselves ...
... Being one of the fastest progressing and spreading diseases of ... going on in this direction and a new study states ... to osteoarthritis. ,The study was conducted at ... the ability of an extract of pomegranate fruit against Interleukin-1b ...
... Vioxx, pain killer which was found to cause the death ... Merck Pharma the manufacturers of Vioxx were asked by the ... to Mrs. Ernst. Over 5 years, about 20 million people ... September 2004, after a clinical trial found irrefutable evidence that ...
... obstetricians urge their pregnant patients to exercise regularly, when ... ,The researcher from Saint Louis University School of ... September issue of a publication for obstetricians and gynecologists. ... exercise in women with healthy pregnancies results in no ...
... tiny delivery vehicles that can carry anticancer therapeutic ... genetic material constructed through nanotechnology, offering a potential ... This emerging branch of science is called nanomedicine. ... are assembled from three short pieces of ribonucleic ...
... through the scientific circles that soft trans fat-free margarines in ... disease. ,The study is one of the many aimed ... risk for coronary heart disease (CHD) was more closely associated ... fat-free margarines made from soybean and canola oil)(1). In fact, ...
Cached Medicine News:Health News:Pomegranate Juice Is Helpful In Arresting Osteoarthritis 2Health News:RNA Nanotechnology To Rescue Cancer Patients In Future 2Health News:PUFA Good For Heart: Gets The Scientific Seal 2
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Medicine Products: